Associated Papers
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T et al.
Esmo Open, 2024
38387111 (PubMed )
Supplement: mmc2.xlsx › Enriched_gene_mutations
Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7.
Boretto M et al.
Proceedings of the National Academy of Sciences of the United States of America, 2024
38483988 (PubMed )
Supplement: pnas.2309902121.sd05.xlsx › Dataset_S5_and_S6
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas.
Omura T et al.
Cancers, 2022
35626060 (PubMed )
Supplement: cancers-14-02454-s001.zip › cancers-1674301-SI.xlsx › VUS
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
Keam B et al.
International Journal of Clinical Oncology, 2014
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X et al.
Amino Acids, 2014
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Kalikaki A et al.
British Journal of Cancer, 2008
Inhibition of cortical neuron differentiation by Groucho/TLE1 requires interaction with WRPW, but not Eh1, repressor peptides.
Buscarlet M et al.
The Journal of Biological Chemistry, 2008
Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.
Liu H et al.
Cancer Control : Journal of the Moffitt Cancer Center, 0
Select a paper to view details